[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.113.179. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Invited Critique
March 1, 2004

Octreotide in the Prevention of Intra-abdominal Complications Following Elective Pancreatic Resection—Invited Critique

Arch Surg. 2004;139(3):295. doi:10.1001/archsurg.139.3.295

Alas, another trial and still no answer. This well-conceived and well-conducted randomized trial fuels the debate and leaves us where we started. All 8 published trials examining the use of prophylactic octreotide have their differences in design and outcome, but the most compelling finding is the transatlantic discord: the European trials favor the use of octreotide, whereas the American trials do not. Because of this it is still not possible to state that administration of prophylactic octreotide is a standard of care following pancreatic resection.

×